ASCENT Trial: Optimizing TKI Therapy for EGFR-Mutant NSCLC Challenges

Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen.

Related Keywords

United States ,American , ,American Joint Committee On Cancer ,American Joint Committee ,Image Credit ,